Clinuvel - Latest News [Page 1]

First Patient Treated In Clinuvel DNA Repair Study

Friday, 22 October 2021, 6:02 pm | Clinuvel

CLINUVEL PHARMACEUTICALS LTD today announced that the first xeroderma pigmentosum (XP) patient has received afamelanotide treatment in the CUV156 study, part of the Company’s DNA Repair Program. The adult XP patient – diagnosed with the XP-C ... More >>

CLINUVEL Progresses Innovative DNA Repair Program

Thursday, 10 September 2020, 6:39 pm | Clinuvel

Drug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE® (afamelanotide 16mg) to treat the disease xeroderma pigmentosum ... More >>

Clinuvel records first A$1 million in sales

Monday, 27 June 2011, 3:33 pm | Clinuvel

Clinuvel Pharmaceuticals Limited ( ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY ) today announced that it has made a successful start to its distribution of its new drug SCENESSE® (afamelanotide) to the erythropoietic protoporphyria (EPP) patient community in Italy. More >>

UV-protective drug to be tested for vitiligo

Wednesday, 25 August 2010, 11:53 am | Clinuvel

A drug initially developed to protect skin from light and UV will soon be tested as a repigmentation therapy in vitiligo, a common disorder which causes skin to gradually lose its pigment or tone. SCENESSE?, a new drug developed in Australia, will be evaluated ... More >>